Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15730571 | 1.00 | ABCB1 (0.48) | ABCB1RIPK1GPR119RORCNR1H2 | |
| SCHEMBL15730078 | 1.00 | ABCB1 (0.48) | ABCB1RIPK1GPR119RORCNR1H2 | |
| SCHEMBL18639491 | 1.00 | ABCB1 (0.48) | ABCB1RIPK1GPR119RORCNR1H2 | |
| SCHEMBL4870228 | 0.91 | ABCB1 (0.52) | ABCB1RIPK1GPR119RORCNR1H2 | |
| SCHEMBL14074143 | 0.91 | ABCB1 (0.52) | ABCB1RIPK1GPR119RORCNR1H2 | |
| SCHEMBL19753721 | 0.87 | ESR2 (0.41) | ABCB1GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL6182669 | 0.86 | ABCB1 (0.48) | ABCB1RIPK1GPR119RORCNR1H2 | |
| SCHEMBL475745 | 0.84 | FFAR2 (0.51) | ABCB1RIPK1GPR119 | |
| SCHEMBL859599 | 0.84 | FFAR2 (0.51) | ABCB1RIPK1GPR119 | |
| SCHEMBL6183606 | 0.84 | FFAR2 (0.51) | ABCB1RIPK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | ABCB1 20/4885RIPK1 2275/4885GPR119 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.